A Phase 3 interventional study of Tislelizumab and Paclitaxel in Non-Small Cell Lung Cancer, sponsored by BeiGene. Completed at 43 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 9 in phase 3, and was the 2nd registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Fujian Cancer Hospital · Sites in China
Ages 18–75
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 28 · Phase 3 10 · Phase 4 2
First in 2017; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 360 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 39 across the 41 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines: none open now, 1 under way, 1 of them phase 3. Of 15 finished, 10 (67%) have results posted.
Among the 16 studies in Carcinoma, Non-Small-Cell Lung by BeOne Medicines, this one is the 6th largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.
BeOne Medicines’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2017.
2 of the studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07320105Fujian Cancer HospitalPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II) | 2027-01-15 |
| NCT07845916Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyQuad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among BeOne Medicines’s 16 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
An open-label, randomized, multicenter Phase 3 study designed to compare the efficacy and safety of tislelizumab combined with chemotherapy versus chemotherapy only as first-line treatment in advanced squamous non-small cell lung cancer (NSCLC).
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tislelizumab 200 milligrams (mg) plus paclitaxel 175 mg/m\^2 and carboplatin area under the plasma or serum concentration-time curve (AUC) 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
Drug: Tislelizumab · Drug: Paclitaxel · Drug: Carboplatin
Tislelizumab 200 mg on Day 1 plus Nab-paclitaxel 100 mg/m\^2 on Days 1, 8, and 15 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks until unacceptable toxicity, withdrawal of consent, loss of clinical benefit, or disease progression; Nab-paclitaxel and carboplatin were administered for 4 to 6 cycles (each cycle is 21 days)
Drug: Tislelizumab · Drug: Nab-paclitaxel · Drug: Carboplatin
Paclitaxel 175 mg/m\^2 and carboplatin AUC 5 on Day 1 administered intravenously once every 3 weeks for 4 to 6 cycles (each cycle is 21 days)
Drug: Paclitaxel · Drug: Carboplatin
Administered intravenously as described
Also known as: BGB-A317, Tevimbra
Administered intravenously as described
Administered intravenously as described
Administered intravenously as described
Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first
Time frame: Through primary analysis data cut-off date of 06DEC2019 (up to approximately 1 year and 4 months)
PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first
Time frame: Through primary analysis data cut-off date of 30SEP2020 (up to approximately 2 years and 2 months)
Overall Survival (OS)
OS is defined as the time from randomization until the date of death due to any cause
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Objective Response Rate (ORR) by IRC Assessment
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
ORR by Investigator Assessment
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
Duration of Response (DOR) by IRC Assessment
DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
DOR by Investigator Assessment
DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
PFS by Investigator Assessment
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells
Time frame: Through study completion data cut-off date of 28APR2023 (up to approximately 4 years and 9 months)
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)
Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
Time frame: Baseline to Cycle 5; each cycle is 21 days
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status
Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 5; each cycle is 21 days
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
Time frame: From first dose to 30 days after the last dose (up to approximately 4 years and 9 months)
This study was conducted at multiple study centers in China. Data are presented as of the study completion data cut-off date of 28APR2023.
| Milestone | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| Started | 120 | 119 | 121 |
| Randomized but not treated | 0 | 1 | 4 |
| Completed | 0 | 0 | 0 |
| Not completed | 120 | 119 | 121 |
| Withdrew: Death | 78 | 86 | 87 |
| Withdrew: Withdrawal by subject | 5 | 2 | 11 |
| Withdrew: Lost to follow-up | 4 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 23 | 17 | 16 |
| Withdrew: Did not meet inclusion criteria | 0 | 0 | 1 |
| Withdrew: Transfer to long term extension study | 10 | 12 | 5 |
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurs first
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| Progression Free Survival (PFS) by Independent Review Committee (IRC) Assessment as of Data Cut-off Date of 06DEC2019 | 7.6 (5.95 to 9.79) | 7.6 (5.75 to 11.01) | 5.5 (4.21 to 5.65) |
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| PFS by IRC Assessment as of Data Cut-off Date of 30SEP2020 | 7.7 (6.74 to 10.41) | 9.6 (7.39 to 10.78) | 5.5 (4.21 to 5.59) |
OS is defined as the time from randomization until the date of death due to any cause
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| Overall Survival (OS) | 26.1 (18.99 to 33.81) | 23.3 (18.76 to 26.38) | 19.4 (15.97 to 23.43) |
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the IRC using RECIST v1.1.
| Percentage of participants | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| Objective Response Rate (ORR) by IRC Assessment | 74.2 (65.4 to 81.7) | 73.9 (65.1 to 81.6) | 47.9 (38.8 to 57.2) |
ORR is defined as the percentage of participants with complete response (CR) and partial response (PR), as assessed by the investigator using RECIST v1.1.
| Percentage of participants | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| ORR by Investigator Assessment | 70.0 (61.0 to 78.0) | 78.2 (69.6 to 85.2) | 49.6 (40.4 to 58.8) |
DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the IRC using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| Duration of Response (DOR) by IRC Assessment | 8.4 (5.03 to 18.69) | 8.6 (7.13 to 12.48) | 4.3 (2.86 to 5.42) |
DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression assessed by the investigator using RECIST v1.1, or death from any cause, whichever comes first, in all randomized participants with documented objective responses. Data are based on number of responders.
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| DOR by Investigator Assessment | 10.6 (7.03 to 16.23) | 8.8 (8.05 to 11.93) | 4.8 (2.86 to 6.11) |
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the investigator per RECIST v1.1 or death from any cause, whichever occurs first
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| PFS by Investigator Assessment | 9.6 (7.62 to 11.76) | 9.8 (8.57 to 11.86) | 5.5 (4.17 to 5.65) |
PFS is defined as the time from randomization until first documentation of disease progression as assessed by the IRC per RECIST v1.1 or death from any cause, whichever occurs first, based on PD-L1 expression in tumor cells
| Months | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| PD-L Expression (<1%) | 7.6 (5.5 to 14.5) | 7.6 (5.4 to 9.9) | 5.5 (4.2 to 7.0) |
| PD-L Expression (1% to 49%) | 9.9 (5.5 to 22.7) | 9.8 (7.6 to 12.0) | 5.0 (2.8 to 6.5) |
| PD-L Expression (≥ 50%) | 7.7 (5.9 to 9.8) | 9.7 (5.6 to 30.9) | 5.5 (4.1 to 5.6) |
Least squares mean change from baseline in EORTC QLQ-CL13 scores for chest pain, coughing, and dyspnea between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.
| Score on a scale | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin |
|---|---|---|
| Chest pain | 0.4 (-5.0 to 5.9) | -0.4 (-5.9 to 5.1) |
| Coughing | -7.0 (-14.3 to 0.2) | -0.4 (-7.7 to 6.8) |
| Dyspnea | -2.7 (-6.9 to 1.6) | -1.0 (-5.3 to 3.3) |
Least squares mean change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score between tislelizumab arms and paclitaxel + carboplatin arm. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer patients. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin |
|---|---|---|
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status | 2.4 (-3.4 to 8.2) | 3.3 (-2.5 to 9.2) |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0
| Participants | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| At least 1 TEAE | 120 | 117 | 117 |
| At least 1 SAE | 56 | 55 | 29 |
Collected over From the first dose up to 30 days after the last dose of study drug, up to approximately 4 years and 9 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab + Paclitaxel + Carboplatin | 78/120 (65%) | 56/120 (46.7%) | 119/120 (99.2%) |
| Tislelizumab + Nab-Paclitaxel + Carboplatin | 86/119 (72.3%) | 55/118 (46.6%) | 117/118 (99.2%) |
| Paclitaxel + Carboplatin | 87/121 (71.9%) | 29/117 (24.8%) | 116/117 (99.1%) |
| Event | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| PneumoniaInfections and infestations | 12/120 | 7/118 | 5/117 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 6/120 | 7/118 | 0/117 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/120 | 4/118 | 1/117 |
| Neutrophil count decreasedInvestigations | 4/120 | 4/118 | 2/117 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 4/120 | 4/118 | 1/117 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/120 | 1/118 | 3/117 |
| AnaemiaBlood and lymphatic system disorders | 1/120 | 1/118 | 2/117 |
| DeathGeneral disorders | 1/120 | 2/118 | 2/117 |
| PyrexiaGeneral disorders | 2/120 | 1/118 | 2/117 |
| Septic shockInfections and infestations | 0/120 | 1/118 | 2/117 |
| Event | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-Paclitaxel + Carboplatin | Paclitaxel + Carboplatin |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 107/120 | 111/118 | 94/117 |
| AlopeciaSkin and subcutaneous tissue disorders | 78/120 | 82/118 | 72/117 |
| Neutrophil count decreasedInvestigations | 78/120 | 73/118 | 68/117 |
| White blood cell count decreasedInvestigations | 68/120 | 68/118 | 61/117 |
| LeukopeniaBlood and lymphatic system disorders | 58/120 | 66/118 | 57/117 |
| NeutropeniaBlood and lymphatic system disorders | 53/120 | 50/118 | 56/117 |
| Alanine aminotransferase increasedInvestigations | 57/120 | 46/118 | 27/117 |
| Decreased appetiteMetabolism and nutrition disorders | 55/120 | 55/118 | 37/117 |
| NauseaGastrointestinal disorders | 37/120 | 54/118 | 35/117 |
| Platelet count decreasedInvestigations | 45/120 | 54/118 | 29/117 |
Intent-to-treat (ITT) analysis set included all participants who were randomized. Data are presented as of the study completion data cut-off date of 28APR2023.
| Age, Continuous(Years) | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|---|
| Median | 60.0 (41 to 75) | 64.0 (38 to 74) | 63.0 (34 to 75) | 62.5 (34 to 75) |
| Sex: Female, Male(Participants) | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|---|
| Female | 13 | 7 | 10 | 30 |
| Male | 107 | 112 | 111 | 330 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab + Paclitaxel + Carboplatin | Tislelizumab + Nab-paclitaxel + Carboplatin | Paclitaxel + Carboplatin | Total |
|---|---|---|---|---|
| Asian | 120 | 119 | 121 | 360 |
| Not Hispanic or Latino | 120 | 119 | 121 | 360 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jul 2018 to primary completion in Sep 2020, 26 months.
Results were first posted in Oct 2023, 3 years after primary completion. A results delay was requested in Sep 2021.
Of 314 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 26 months is below that.
Counting every sponsor, half of 423 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Paclitaxel · Albumin-Bound Paclitaxel
Carcinoma, Non-Small-Cell Lung →